Efficacy of bevacizumab and chemotherapy in the first-line treatment of metastatic colorectal cancer: broadening KRAS-focused clinical view

BMC Gastroenterology

Research Article

Jana Halamkova¹  Igor Kiss²  Beatrix Bencsikova²  Rostislav Vyzula³  Lenka Ostrizkova⁴  Bohuslav Melichar⁵  Zbynek Bortlicek⁶  Ladislav Dusek⁶  Tomas Pavlik⁶  Dalibor Valik⁷  Lenka Zdrazilova-Dubska⁸ 

[1] Department of Complex Oncology Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic;Department of Complex Oncology Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic;Regional Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Brno, Czech Republic;Department of Complex Oncology Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic;Regional Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Brno, Czech Republic;Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic;Department of Internal Medicine and Hematooncology, University Hospital Brno, Brno, Czech Republic;Department of Oncology, Palacky University Medical School and Teaching Hospital, Olomouc, Czech Republic;Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic;Regional Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Brno, Czech Republic;Department of Laboratory Medicine, Masaryk Memorial Cancer Institute, Zluty kopec 7, 656 53, Brno, Czech Republic;Regional Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Brno, Czech Republic;Department of Laboratory Medicine, Masaryk Memorial Cancer Institute, Zluty kopec 7, 656 53, Brno, Czech Republic;Department of Pharmacology, Faculty of Medicine, Masaryk University, Brno, Czech Republic;

关键词: Colorectal cancer;    Angiogenesis inhibitors;    Bevacizumab;    KRAS;    Biomarkers;    Antineoplastic agents;    Clinical practice;   

DOI  :  10.1186/s12876-015-0266-6

 received in 2014-04-08, accepted in 2015-03-11,  发布年份 2015

来源: Springer

【 摘 要 】

BackgroundThe aim of the present retrospective study was to analyze clinical outcome and risk factors associated with treatment outcomes according to KRAS status in patient with metastatic colorectal cancer (mCRC) treated with bevacizumab (bev) plus chemotherapy in the first-line setting.MethodsWe performed observational study on 1622 patients with mCRC treated with bev plus oxaliplatin- or irinotecan-based chemotherapy, and correlated treatment outcomes with KRAS mutation status. The primary endpoint was progression-free survival (PFS) and additionally overall survival (OS). Adverse events of bevacizumab and risk factors including location of metastases were evaluated.ResultsMutation in KRAS was present in 40.6% of mCRC cases. The median PFS in patients with wild-type KRAS (wtKRAS) vs mutant KRAS was 11.5 vs 11.4 months, respectively. The median OS was 30.7 vs 28.4 months (p = 0.312). Patients with KRAS mutation had lung metastases more frequently than wtKRAS individuals (32.0% vs 23.8%; p = 0.001). We observed no difference in clinical outcome between hepatic and extrahepatic metastatic disease.ConclusionKRAS mutation does not interfere with clinical benefit from first-line treatment with bevacizumab plus chemotherapy in mCRC patients.

【 授权许可】

Unknown   
© Bencsikova et al.; licensee BioMed Central. 2015. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.